Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Area of Science:

• Cardiovascular research
• Hematology
• Immunology

Background:

• Cardiovascular and cerebrovascular diseases are leading global causes of death.
• Pathological thrombus formation from uncontrolled platelet aggregation drives these diseases, often linked to atherosclerotic plaque rupture.
• Current antiplatelet drugs carry a significant risk of spontaneous bleeding due to their interference with normal hemostasis.

Purpose of the Study:

• To develop a safer antiplatelet strategy that prevents thrombosis while preserving hemostasis.
• To target specific activation pathways of integrin αIIbβ3 involved in pathological thrombosis.

Main Methods:

• Developed an antibody targeting the β-tail domain of integrin β3.
• The antibody selectively blocks force-induced topological changes in the integrin transmembrane domain.
• Evaluated the antibody's efficacy in ex vivo and in vivo models of platelet aggregation.

Main Results:

• The developed antibody selectively inhibits force-dependent integrin αIIbβ3 activation.
• Demonstrated suppression of platelet aggregation in both ex vivo and in vivo models.
• Observed no increased bleeding risk associated with the antibody treatment.

Conclusions:

• Targeting force-induced integrin β3 activation offers a promising therapeutic strategy for thrombosis prevention.
• This approach addresses the critical limitation of bleeding risk associated with current antiplatelet therapies.
• The developed antibody represents a potential new avenue for safer antithrombotic treatment.